Cat. No JK976408_50_MG
J&K Chemical

Product Information

Product Name
Regorafenib, 98%, a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively
Brand Name
J&K
Product Number
976408
CAS
755037-03-7
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.82
SDS Document
Certificate of Analysis (COA)​
COA not found

General Information

Synonyms
BAY 73-4506
PubChem CID
11167602
IUPAC Name
4-4-4-chloro-3-(trifluoromethyl)phenylcarbamoylamino-3-fluorophenoxy-N-methylpyridine-2-carboxamide
InChI Key
FNHKPVJBJVTLMP-UHFFFAOYSA-N
SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F

Properties

Melting Point
204-206

Safety Information

GHS Symbols
Hazard Symbol
Signal Word
Warning
Hazard Statement
H317
H319
Precautionary Statement
P261
P272
P280
P321
P501
P302+P352
P333+P317
P362+P364
P264+P265
P305+P351+P338
P337+P317
Storage Condition
Freezer -20℃

References Data Source From Pubchem

Regorafenib

Publication Name: Reactions Weekly
Publication Date: 2026-02-28
DOI: 10.1007/s40278-026-92827-2

Exploring the Potential Anti-Hepatocellular Carcinoma Activity of Jatrorrhizine Through Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation

Publication Name: Journal of Pharmaceutical Innovation
Publication Date: 2026-02-27
DOI: 10.1007/s12247-026-10493-2

Using the EVendo Score to Predict Varices and Varices Needing Treatment in Hepatocellular Carcinoma Patients Planned for Atezolizumab-Bevacizumab

Publication Name: Digestive Diseases and Sciences
Publication Date: 2026-02-26
DOI: 10.1007/s10620-026-09776-y

Correction: In-silico analysis of multi-pathway crosstalk inhibition of santamarin in hepatocellular carcinoma

Publication Name: Journal of Molecular Histology
Publication Date: 2026-02-21
DOI: 10.1007/s10735-026-10744-z|10.1007/s10735-026-10796-1

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling

Publication Name: Nature reviews. Clinical oncology
Publication Date: 2026-02-20
DOI: 10.1038/s41571-026-01126-1

Regorafenib, 98%, a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively

Just added to your wishlist:
My Wishlist
You've just added this product to the cart:
Go to cart page